Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 10/12/04 → 09/26/07 |
Funding
- PPD Incorporated: $95,950.00
MedImmune Protocol MI-CP110: A Pivotal Phase 3 Study of MEDI-524(Numax) an Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody for the Prophylaxis of Serious RSV Disease in High-Risk Children
- Nachman, Sharon (PI)
Project: Research